Journal
BIOMEDICINES
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines11020617
Keywords
HIV-1 latency; ARVs; nanomedicine; exosomes; shock and kill; block and lock
Ask authors/readers for more resources
Antiretrovirals (ARVs) can reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist in cellular reservoirs due to certain ARVs' inability to cross anatomical barriers and HIV-1's ability to establish latent infection. Nanomedicine has been used to improve ARV delivery and efficacy in HIV eradication strategies. This review focuses on HIV-1 latency mechanisms and nanomedicine-based approaches for treating HIV.
Antiretrovirals (ARVs) reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist throughout the body in cellular reservoirs partly due to the inability of some ARVs to cross anatomical barriers and the capacity of HIV-1 to establish latent infection in resting CD4+ T cells and monocytes/macrophages. A cure for HIV is not likely unless latency is addressed and delivery of ARVs to cellular reservoir sites is improved. Nanomedicine has been used in ARV formulations to improve delivery and efficacy. More specifically, researchers are exploring the benefit of using nanoparticles to improve ARVs and nanomedicine in HIV eradication strategies such as shock and kill, block and lock, and others. This review will focus on mechanisms of HIV-1 latency and nanomedicine-based approaches to treat HIV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available